Add source Login
Danish balas sindiran 'menggelupur' Akmal Saleh

Danish balas sindiran 'menggelupur' Akmal Saleh

SHAH ALAM - Ketua Penerangan Angkatan Muda Keadilan (AMK), Danish Hairudin membalas sindiran Ketua Pemuda UMNO, Datuk Dr Muhamad Akmal Saleh yang menyifatkan pihaknya sebagai 'menggelupur'.Danish menerusi hantaran balas di Facebook turut menyampaikan salam 6-0 kepada UMNO Melaka.Meskipun tidak memperincikan maksud 6-0 tersebut, difahamkan ia berkaitan keputusan Pilihan Raya Umum ke-15 (PRU15) bagi enam kerusi Parlimen di Melaka yang menyaksikan UMNO tewas kesemuanya."Dia yang menggelupur. Kita on. Salam 6-0 kepada UMNO Melaka," katanya pada Khamis.Sebelum ini, Dr Muhamad Akmal menyindir pihak yang tidak berpuas hati dengan cadangan beliau mengenai penyatuan UMNO dan Pas di Melaka.Menurut Ahli Dewan Undangan Negeri (ADUN) Merlimau itu, lebih menghairankan lagi kritikan tersebut dibuat oleh parti lain, bukannya UMNO dan Pas.Terdahulu, kenyataan beliau menerusi sesi temu bual audio siar pada Rabu dikritik Danish.Danish mendakwa, pandangan peribadi disuarakan Dr Muhamad Akmal memperlihatkan kegelisahan politik yang sedang melanda parti berkenaan.Beliau menegaskan, cadangan tersebut tidak mendatangkan sebarang ketakutan kepada AMK, sebaliknya yakin ia membuka ruang lebih luas buat Pakatan Harapan (PH).Menurutnya lagi, meskipun rekod semasa di negeri berkenaan menyaksikan Pas tidak memenangi sebarang kerusi pada pilihan raya lalu dan UMNO menang 21 daripada 28 kerusi, namun beliau menekankan isu penyatuan Melayu tidak boleh dilihat semata-mata daripada sudut pembahagian kerusi atau kekuatan parti.

Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia

Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia

- Comprehensive review of recent milestones highlights statistically significant efficacy in prostate cancer prevention, discovery of novel lipid-modulating properties, and the execution of high-value commercial partnerships in South Korea and Vietnam. NEW TAIPEI CITY, Feb. 13, 2026 /PRNewswire/ -- Jyong Biotech... The post Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia appeared first on Kosmo Digital .

Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer

Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer

SAN FRANCISCO and SUZHOU, China, Feb. 13, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent",HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases,... The post Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer appeared first on Kosmo Digital .

Uluṟu’s Global Art Icon ‘Field of Light’ Marks 10 Years with Public Celebrations

Uluṟu’s Global Art Icon ‘Field of Light’ Marks 10 Years with Public Celebrations

Bruce Munro's original installation reaches 750,000 visitors as new art, guest experiences and cultural collaborations are unveiled by Ayers Rock Resort, Uluṟu. SYDNEY, Feb. 13, 2026 /PRNewswire/ -- One of the world's most recognisable large-scale light installations, Bruce Munro's Field of Light,... The post Uluṟu’s Global Art Icon ‘Field of Light’ Marks 10 Years with Public Celebrations appeared first on Kosmo Digital .